Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TroVax versus placebo in relapsed asymptomatic ovarian, fallopian tube, or primary peritoneal cancer
2011-001836-44Phase 2Completed
- Sponsor
- University College London
- Start
- Oct 2012
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) comparing TroVax with Placebo (2 arms). Primary endpoints: Protocol-defined progression at 25 weeks and Protocol-defined progression at 49 weeks. Started Oct 2012; status: completed.
02
Drugs
MVA-5T4
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2011-001836-44.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001836-44.